Alkermes Reports Q3 2025 Financial Results with $82.8M Net Income and Proposed Acquisition of Avadel Pharmaceuticals

Alkermes plc reported its financial results for the third quarter of 2025, revealing a net income of $82.8 million, or $0.50 per ordinary share, compared to $92.8 million, or $0.57 per share, in the same period last year. For the nine months ending September 30, 2025, the company recorded a net income of $192.3 million, down from $226.4 million in the prior year. Total revenues for the third quarter increased to $394.2 million from $378.1 million, driven primarily by a rise in product sales, which reached $317.4 million, up from $273.0 million in the previous year. However, manufacturing and royalty revenues fell significantly, contributing to a decrease in overall profitability.

The company experienced a notable increase in total expenses, which rose by $31.7 million in the third quarter, largely due to higher research and development (R&D) and selling, general, and administrative expenses. R&D expenses alone increased to $81.7 million from $59.8 million year-over-year, reflecting Alkermes' commitment to advancing its pipeline, particularly the development of Alixorexton, an investigational treatment for narcolepsy. The company also reported a decrease in the cost of goods sold, which fell to $51.6 million from $63.1 million, attributed to reduced costs associated with legacy products following the sale of its Athlone facility in May 2024.

In terms of operational metrics, Alkermes noted a 19% increase in the number of units sold for its product LYBALVI during the nine months ended September 30, 2025, contributing to a total product sales increase. The company also reported a decrease in Medicaid rebates as a percentage of sales, indicating improved gross-to-net favorability. However, manufacturing and royalty revenues were adversely affected by the expiration of royalties on INVEGA SUSTENNA, which had previously constituted a significant revenue source.

Strategically, Alkermes announced a proposed acquisition of Avadel Pharmaceuticals for $18.50 per share, with a total potential consideration of up to $20.00 per share, contingent on achieving certain milestones. This acquisition is expected to be completed in the first quarter of 2026, subject to shareholder and regulatory approvals. The company has secured a bridge loan facility of approximately $1.2 billion to finance the acquisition, alongside placing $700 million of its cash into an escrow account for the transaction.

Looking ahead, Alkermes anticipates continued investment in its R&D pipeline and expects to incur costs of approximately $15 million to $20 million related to the acquisition in the fourth quarter of 2025. The company remains focused on leveraging its existing cash and investments to support its operational and strategic initiatives, projecting that its current financial resources will be sufficient to meet its working capital needs for at least the next twelve months.